Athersys, Inc. (ATHX) EVP John J. Harrington Sells 7,500 Shares
Athersys, Inc. (NASDAQ:ATHX) EVP John J. Harrington sold 7,500 shares of Athersys stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $1.68, for a total value of $12,600.00. Following the completion of the transaction, the executive vice president now directly owns 658,474 shares of the company’s stock, valued at $1,106,236.32. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Shares of Athersys, Inc. (ATHX) traded up $0.07 on Tuesday, hitting $1.86. The stock had a trading volume of 851,601 shares, compared to its average volume of 1,016,421. Athersys, Inc. has a 12 month low of $1.02 and a 12 month high of $2.63.
Several research analysts have recently weighed in on the company. ValuEngine lowered Athersys from a “hold” rating to a “sell” rating in a research report on Tuesday, December 5th. Maxim Group set a $12.00 price objective on Athersys and gave the stock a “buy” rating in a research report on Thursday, November 16th. Finally, Zacks Investment Research lowered Athersys from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. Athersys has an average rating of “Hold” and an average price target of $7.17.
TRADEMARK VIOLATION WARNING: “Athersys, Inc. (ATHX) EVP John J. Harrington Sells 7,500 Shares” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/19/athersys-inc-athx-evp-john-j-harrington-sells-7500-shares.html.
Athersys Company Profile
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.